00:15:13 EDT Thu 13 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Revive Therapeutics Ltd
Symbol RVV
Shares Issued 357,646,841
Close 2023-12-19 C$ 0.03
Market Cap C$ 10,729,405
Recent Sedar Documents

Revive shareholders approve all matters at AGSM

2023-12-20 13:11 ET - News Release

Mr. Michael Frank reports

REVIVE THERAPEUTICS ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

Revive Therapeutics Ltd. has released the results of its annual general and special meeting of shareholders held Tuesday, Dec. 19, 2023, in Toronto, Ont. All matters presented to the shareholders of the company for approval as set out in the company's notice of meeting and information circular, dated Nov. 10, 2023, respectively, were approved by an overwhelming majority of votes cast at the meeting. Of the 357,646,841 shares issued and outstanding on the record date for the meeting, 143,297,862 shares, being 40 per cent of the shares, were voted.

Shareholders of the company re-elected Michael Frank, Joshua Herman, William L.C. Jackson, Andrew S. Lindzon and Christian Scovenna for the ensuing year.

The shareholders of the company reappointed Clearhouse LLP, chartered professional accountants, as the company's auditor for the ensuing year, and authorized the board of directors to fix the remuneration to be paid to the auditor.

In addition, the shareholders approved the company's 10 per cent rolling stock option plan, whereby the company is authorized to issue options under the option plan to acquire up to 10 per cent of the then-issued and outstanding common shares in the capital of the company at the time of grant.

Following the meeting, the board of directors reappointed Michael Frank as executive chairman and chief executive officer, and Carmelo Marrelli as chief financial officer and corporate secretary.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as emergency use authorization, orphan drug, fast-track and breakthrough therapy designations. Currently, the company is exploring the use of bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of psilocybin-based therapeutics through various programs.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.